Glutathione-Driven Redox Inducer with Disruption of the SLC7A11/GSH/GPX4 Axis for Enhanced Ferroptotic Therapy
Langmuir · 2026
DOI: 10.1021/acs.langmuir.6c04327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Langmuir, 2026. Verfasst von Sen Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences and Health Engineering, Jiangnan University, Wuxi214122, China. Hauptthemen laut MEDLINE: Amino Acid Transport System y+, Phospholipid Hydroperoxide Glutathione Peroxidase, Glutathione, Ferroptosis. Die Arbeit nennt 60 Literaturangaben. Gefördert von: 2024 "Wild Goose Array Talents" Discipline Leader Fund of Wuxi People?s Hospital, Medical Innovation Team of Wuxi, Top Medical Expert Team of the 2021 Taihu Talent Plan Project.
Abstract (Originalsprache)
Non-small-cell lung cancer (NSCLC) is a lethal malignant tumor worldwide. Although ferroptosis offers a promising route for curcumin-mediated non-small-cell lung cancer therapy, its efficacy is often constrained by the robust antioxidant defense maintained by the SLC7A11/GSH/GPX4 axis, which continuously sustains cystine uptake, glutathione biosynthesis, and GPX4-dependent lipid peroxide detoxification, thereby maintaining cellular homeostasis. Herein, we developed a glutathione-responsive metal–organic framework nanoplatform for the co-delivery of curcumin and a GPX4-targeting antisense oligonucleotide (ASO). After cellular internalization, the disulfide-bearing framework underwent GSH-triggered disassembly, enabling synchronized release of curcumin and ASO while depleting the intracellular GSH. Released curcumin increased ROS accumulation and disturbed redox homeostasis, whereas ASO silenced GPX4 expression to concurrently disable the antioxidant defense. Flow cytometry and Western blot assays confirmed significant ROS accumulation and SLC7A11 downregulation, which were detailed by molecular dynamics simulations with putative binding modes. Furthermore, the nanocomposite demonstrated robust anticancer effects in 3D multicellular tumor spheroids with a promoted oxidative imbalance. Taken together, this coordinated intervention disrupted the SLC7A11/GSH/GPX4 antioxidant axis, amplified lipid peroxidation, impaired mitochondrial function, and ultimately enhanced ferroptotic vulnerability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Life Sciences and Health Engineering, Jiangnan University, Wuxi214122, China.
- Department of Oncology, Wuxi People's Hospital, Wuxi214023, China.
- Wuxi School of Medicine, Jiangnan University, Wuxi214122, China.
- School of Chemical and Material Engineering, Jiangnan University, Wuxi214122, China.
ORCID-Profile: Zhaoqi Yang
Förderung
- 2024 "Wild Goose Array Talents" Discipline Leader Fund of Wuxi People?s Hospital
- Medical Innovation Team of Wuxi
- Top Medical Expert Team of the 2021 Taihu Talent Plan Project
- Postgraduate Research and Practice Innovation Program of Jiangsu Province
- 2025 "Wild Goose Array Talents" Discipline Leader Fund of Wuxi People?s Hospital
Zitieren
APA
Li, S., Wang, W., Chen, Y., Shao, Q., Yang, Z., & Hua, D. (2026). Glutathione-Driven Redox Inducer with Disruption of the SLC7A11/GSH/GPX4 Axis for Enhanced Ferroptotic Therapy. Langmuir. https://doi.org/10.1021/acs.langmuir.6c04327
Vancouver
Li S, Wang W, Chen Y, Shao Q, Yang Z, Hua D. Glutathione-Driven Redox Inducer with Disruption of the SLC7A11/GSH/GPX4 Axis for Enhanced Ferroptotic Therapy. Langmuir. 2026. doi:10.1021/acs.langmuir.6c04327
BibTeX
@article{Li2026,
author = {Li, Sen and Wang, Wentao and Chen, Yizhang and Shao, Qiuze and Yang, Zhaoqi and Hua, Dong},
title = {Glutathione-Driven Redox Inducer with Disruption of the SLC7A11/GSH/GPX4 Axis for Enhanced Ferroptotic Therapy},
journal = {Langmuir},
year = {2026},
doi = {10.1021/acs.langmuir.6c04327}
}
EUVIMED